News coverage about OraSure Technologies (NASDAQ:OSUR) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OraSure Technologies earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 45.8783381978795 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Watching the Tape Move for OraSure Technologies Inc (OSUR) and Cara Therapeutics Inc (CARA) - Evergreen Caller (evergreencaller.com)
- Is The Needle Ready to Move For OraSure Technologies Inc (OSUR) Shares? - FLBC News (flbcnews.com)
- OraSure Technologies, Inc. (NASDAQ:OSUR) Stock Traded Higher Than Its 50 Day Moving Average - Modern Readers (modernreaders.com)
- Can OraSure (OSUR) Run Higher on Strong Earnings Estimate Revisions? - Nasdaq (nasdaq.com)
Several equities research analysts have recently commented on the stock. Jefferies Group LLC lifted their price objective on shares of OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, June 28th. BidaskClub downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Canaccord Genuity lifted their price objective on shares of OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Stephens reiterated an “overweight” rating and set a $19.00 price objective (up from $14.00) on shares of OraSure Technologies in a research note on Tuesday, July 11th. Finally, Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Saturday, May 6th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $15.46.
OraSure Technologies (OSUR) traded up 0.24% during midday trading on Thursday, hitting $20.57. 275,656 shares of the stock traded hands. The company has a 50-day moving average price of $19.21 and a 200 day moving average price of $14.79. OraSure Technologies has a one year low of $7.09 and a one year high of $21.59. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 38.02 and a beta of 1.57.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 EPS for the quarter, beating the consensus estimate of $0.07 by $0.02. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The company had revenue of $40.18 million for the quarter, compared to the consensus estimate of $36.54 million. During the same quarter last year, the company posted $0.07 earnings per share. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. Equities research analysts anticipate that OraSure Technologies will post $0.48 earnings per share for the current year.
In other OraSure Technologies news, Director Ronny B. Lancaster sold 89,684 shares of the stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $14.79, for a total transaction of $1,326,426.36. Following the transaction, the director now owns 6,295 shares in the company, valued at $93,103.05. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Douglas A. Michels sold 290,495 shares of the stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $16.75, for a total value of $4,865,791.25. Following the transaction, the chief executive officer now owns 894,012 shares in the company, valued at approximately $14,974,701. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,036,670 shares of company stock worth $19,807,152. Corporate insiders own 6.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: “OraSure Technologies (OSUR) Receiving Somewhat Favorable Press Coverage, Accern Reports” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://stocknewstimes.com/2017/08/24/orasure-technologies-osur-receiving-somewhat-favorable-press-coverage-accern-reports.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
